Relationship between the genetic variants in SLCOI B1 gene and the response to repaglinide treatment in newly-diagnosed type 2 diabetic patients
10.3760/cma.j.issn.1000-6699.2009.01.013
- VernacularTitle:有机阴离子转运蛋白1B1基因多态性与瑞格列奈药物疗效的关系
- Author:
Rong ZHANG
;
Cheng HU
;
Congrong WANG
;
Xinyu SHAO
;
Yuqian BAO
;
Xiaojing MA
;
Kunsan XIANG
;
Weiping JIA
- Publication Type:Journal Article
- Keywords:
Gene;
Polymorphism,single nucleotide;
Diabetes mellitus,type 2;
Repaglinide;
Pharmacogenetics
- From:
Chinese Journal of Endocrinology and Metabolism
2009;25(1):46-48
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of solute cartier organic anion transporter family, member 1B1 (SLCOIBI) gene variants on the response to therapy with repaglinide in type 2 diabetes. Methods 100 newly-diagnosed type 2 diabetic patients were treated with repaglinide during a course of 48 weeks. Anthropometrie parameters and indices related to glucose metabolism were measured periodically. Genotypes of SLCO1B1 D130N and V174A were detected by PCR-restriction fragment length polymorphism (RFLP) and sequencing respectively. Results Eighty-nine patients accomplished the 48-week follow-up visits. D130N variant in SLCO1B1 gene was associated with repaglinide treatment, DD genotype had better HbA1C lowering effect than N allele carrier [△HbA1C: (-2.29±0.23) % vs (-1.49±0.21)%, P<0.05]. No association was detected between D130N and the other effects of repaglinide on glucose metabolism related phenotypes. Conclusion D130N variant in SLCO1B1 gene is associated with the response to repaglinide treatment in patients with type 2 diabetes. DD homozygotes had a better effect than N allele carriers.
